Literature DB >> 10677866

Identification of homozygous and heterozygous dy2J mice by PCR.

J T Vilquin1, N Vignier, J P Tremblay, E Engvall, K Schwartz, M Fiszman.   

Abstract

The dystrophia muscularis dy2J/dy2J mouse is an animal model for one form of human congenital muscular dystrophy. A point mutation in the gene coding for the laminin-2 alpha 2 chain leads to the expression of a truncated, partially functional protein. We developed a simple assay for the detection of the dy2J allele, which contains a new NdeI restriction site. Genomic DNA was prepared from animals of known status and amplified by PCR. The digestion of the PCR product with the restriction enzyme resulted in characteristic profiles. Then, this technique was used to identify heterozygous mice among unaffected animals of unknown status. Subsequently, the heterozygous genotype of these mice was confirmed by the birth of dystrophic offspring after mating. This technique allows the detection of the dy2J allele in heterozygous and homozygous animals at any age.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677866     DOI: 10.1016/s0960-8966(99)00056-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Chimeric protein repair of laminin polymerization ameliorates muscular dystrophy phenotype.

Authors:  Karen K McKee; Stephanie C Crosson; Sarina Meinen; Judith R Reinhard; Markus A Rüegg; Peter D Yurchenco
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

Review 2.  Animal models for genetic neuromuscular diseases.

Authors:  Mariz Vainzof; Danielle Ayub-Guerrieri; Paula C G Onofre; Poliana C M Martins; Vanessa F Lopes; Dinorah Zilberztajn; Lucas S Maia; Karen Sell; Lydia U Yamamoto
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

3.  The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.

Authors:  Yoram Nevo; Shlomit Aga-Mizrachi; Edva Elmakayes; Nurit Yanay; Keren Ettinger; Moran Elbaz; Zivia Brunschwig; Oshrat Dadush; Galit Elad-Sfadia; Roni Haklai; Yoel Kloog; Joab Chapman; Shimon Reif
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

4.  Coordinate control of axon defasciculation and myelination by laminin-2 and -8.

Authors:  Dongren Yang; Jesse Bierman; Yukie S Tarumi; Yong-Ping Zhong; Reshma Rangwala; Thomas M Proctor; Yuko Miyagoe-Suzuki; Shin'ichi Takeda; Jeffrey H Miner; Larry S Sherman; Bruce G Gold; Bruce L Patton
Journal:  J Cell Biol       Date:  2005-02-07       Impact factor: 10.539

5.  Optimal myelin elongation relies on YAP activation by axonal growth and inhibition by Crb3/Hippo pathway.

Authors:  Ruani N Fernando; Laurent Cotter; Claire Perrin-Tricaud; Jade Berthelot; Sylvain Bartolami; Jorge A Pereira; Sergio Gonzalez; Ueli Suter; Nicolas Tricaud
Journal:  Nat Commun       Date:  2016-07-20       Impact factor: 14.919

6.  Amelioration of muscle and nerve pathology of Lama2-related dystrophy by AAV9-laminin-αLN linker protein.

Authors:  Karen K McKee; Peter D Yurchenco
Journal:  JCI Insight       Date:  2022-07-08

7.  Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.

Authors:  M Elbaz; N Yanay; S Laban; M Rabie; S Mitrani-Rosenbaum; Y Nevo
Journal:  Cell Death Dis       Date:  2015-03-12       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.